Hyperphosphatemia

Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.

In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.

In a study of hemodialysis patients, PAD risk increased nonlinearly with serum phosphate level.

In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.

If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.

In a 2-day dietary intervention study, very-low-phosphate and low-phosphate diets decreased fibroblast growth factor 23 levels to a similar degree in patients on hemodialysis, but the very-low-phosphate diets results in greater lowering of phosphorus levels.